Tableau Software Price Target Raised to $70.00 at BMO Capital Markets (DATA)

Research analysts at BMO Capital Markets boosted their price objective on shares of Tableau Software (NYSE:DATA) from $57.00 to $70.00 in a report released on Friday, Stock Ratings Network.com reports. The firm currently has a “market perform” rating on the stock. BMO Capital Markets’ target price would indicate a potential upside of 3.21% from the stock’s previous close.

Shares of Tableau Software (NYSE:DATA) traded up 11.29% during mid-day trading on Friday, hitting $67.82. Tableau Software has a 52 week low of $0.21 and a 52 week high of $0.65. The stock’s 50-day moving average is currently $0.41. The company’s market cap is $3.901 billion.

Tableau Software (NYSE:DATA) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.01 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.17) by $0.18. The company had revenue of $49.90 million for the quarter, compared to the consensus estimate of $29.11 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. The company’s quarterly revenue was up 71.5% on a year-over-year basis.

A number of other firms have also recently commented on DATA. Analysts at Susquehanna initiated coverage on shares of Tableau Software in a research note to investors on Tuesday, July 16th. They set a “neutral” rating on the stock. Separately, analysts at Pacific Crest initiated coverage on shares of Tableau Software in a research note to investors on Monday, July 8th. They set a “sector perform” rating on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of Tableau Software in a research note to investors on Tuesday, June 11th.

Ten research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $59.67.

DATATRAK International, Inc (NYSE:DATA) is a technology and services company focused on global eClinical solutions for the clinical trials industry.